Skip to Main Content

Back to Events

The Noreen O'Neill Melanoma Research Virtual Symposium: Understanding Melanoma Progression and Therapy Resistance

Symposium
Wednesday, Jun. 16, 2021 12:00 p.m. to 4:00 p.m.

Melanoma is an aggressive, highly heterogeneous disease. Targeted therapies and immunotherapies have brought a substantial improvement in overall patient survival, but long-term success of these treatments is hindered by therapy resistance. While a number of molecular mechanisms underlying resistance and approaches to bypass it are under investigation, many challenges remain ahead. During the symposium, you will hear about new models and strategies to investigate key aspects of melanoma progression and metastasis and novel approaches to overcome therapy resistance.

*Symposium held via GoToWebinar.

Register Today

 

12:00 - 12:10 PM  

Welcome
Meenhard Herlyn, D.V.M., D.Sc.
Professor, Molecular & Cellular Oncogenesis Program
Director, The Wistar Institute Melanoma Research Center
The Wistar Institute

Jessie Villanueva, Ph.D.
Associate Professor, Molecular and Cellular Oncogenesis Program
Member, The Wistar Institute Melanoma Research Center
The Wistar Institute

12:10 - 12:35 PM  

“Deciphering Clinically Relevant Neoantigenic Landscapes in Melanoma”
Yardena Samuels, Ph.D.
Associate Professor, Molecular & Cell Biology
The Knell Family Professor
Weizmann Institute of Science

12:35 - 1:00 PM  

“Harnessing RNA Splicing to Improve Cancer Immunotherapy”
Michal Lotem, M.D.    
Head, Center for Melanoma and Cancer Immunotherapy
The Concern Foundation Laboratories
The Lautenberg Center for Immunology and Cancer Research

1:00 - 1:25 PM  

"Dissecting Intratumor Heterogeneity in Primary Uveal Melanomas”
Corine Bertolotto, Ph.D.
Team Leader, Research Director INSERM
Université Côte d’Azur

1:25 - 1:50 PM  

“Editing the Melanoma Genome Base-by-base”
David Adams, Ph.D.
Senior Group Leader
Head, Experimental Cancer Genetics
Wellcome Trust Sanger Institute

1:50 - 2:00 PM  

Break

2:00 - 2:25 PM  

“Defining and Targeting the MITF-low/neural Crest-like Cells Resistance to Targeted and Immunotherapy”
Keith Flaherty, M.D.
Director of Clinical Research, Cancer Center
Massachusetts General Hospital

2:25  - 2:50 PM  

“Tumor Escape Routes from Effective Targeted Therapies: Dedifferentiation,
Trans-differentiation, Extrachromosomal DNA (ecDNA) Amplification; and New
Resulting Vulnerabilities Such as Ferroptosis”

Thomas Graeber, Ph.D.
Professor
Director, UCLA Metabolomics Center
University of California, Los Angeles

2:50  - 3:15 PM  

“The Mutational Landscape of Untreated Early Stage Primary Melanoma” 
Marianne Berwick, Ph.D.
Distinguished Professor, Department of Internal Medicine, Division of Epidemiology
Associate Director, Cancer Population Sciences
University of New Mexico

3:15 - 3:40 PM  

Overcoming Obstacles to Response to Checkpoint Blockade Immunotherapy” 
Jedd D. Wolchok, M.D., Ph.D.
Chief, Melanoma and Immunotherapeutics Service
Lloyd J. Old Chair for Clinical Investigation
Memorial Sloan Kettering Cancer Center

3:40 PM  

Closing Remarks
Meenhard Herlyn, D.V.M., D.Sc.
Professor, Molecular & Cellular Oncogenesis Program
Director, The Wistar Institute Melanoma Research Center
The Wistar Institute

Jessie Villanueva, Ph.D.
Associate Professor, Molecular and Cellular Oncogenesis Program
Member, The Wistar Institute Melanoma Research Center
The Wistar Institute

David Adams_final

David Adams, Ph.D.
Wellcome Sanger Institute

View bio.

Corine Bertolotto, Ph.D.

Corine Bertolotto, Ph.D.
University of Nice Sophia Antipolis

View bio.

Marianne Berwick, Ph.D.

Marianne Berwick, Ph.D.
University of New Mexico

View bio.

Keith Flaherty, M.D.

Keith Flaherty, M.D.
Massachusetts General Hospital

View bio.

Thomas Graeber, Ph.D.

Thomas Graeber, Ph.D.
University of California, Los Angeles

View bio. 

Michal Lotem, M.D.

Michal Lotem, M.D.
The Concern Foundation Laboratories at The Lautenberg Center for Immunology and Cancer Research

View bio. 

Yardena Samuels, Ph.D.

Yardena Samuels, Ph.D.
Weizmann Institute of Science

View bio. 

Jedd D. Wolchok, M.D., Ph.D.

Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

View bio.